about
Role of CHK2 in cancer developmentKRAS mutations in primary colorectal cancer tumors and related metastases: a potential role in prediction of lung metastasisA critical role for choline kinase-alpha in the aggressiveness of bladder carcinomasPI3K/Akt signalling pathway and cancer.Implications of oxidative stress and cell membrane lipid peroxidation in human cancer (Spain).Foot pain: uncommon presentation of lung cancer.Lung adenocarcinoma in the era of targeted therapies: histological classification, sample prioritization, and predictive biomarkersMolecular markers in colorectal cancer: genetic bases for a customised treatment.EGFR and colon cancer: a clinical view.Epidermal growth factor receptor and glioblastoma multiforme: molecular basis for a new approach.A role for cancer stem cells in drug resistance and metastasis in non-small-cell lung cancer.Metformin: a new option in cancer treatment.Treatment for ALK-mutated non-small-cell lung cancer: a new miracle in the research race.IGFBP-3 hypermethylation-derived deficiency mediates cisplatin resistance in non-small-cell lung cancer.Targeting Chk2 improves gastric cancer chemotherapy by impairing DNA damage repair.Control of oncologic pain in relief of suffering. Our experience.IGFBP-3 methylation-derived deficiency mediates the resistance to cisplatin through the activation of the IGFIR/Akt pathway in non-small cell lung cancer.Translational proteomics: what can you do for true patients?Prognostic value of carcinoembryonic antigen level in rectal cancer treated with neoadjuvant chemoradiotherapy.Expression of choline kinase alpha to predict outcome in patients with early-stage non-small-cell lung cancer: a retrospective study.MKP1/CL100 controls tumor growth and sensitivity to cisplatin in non-small-cell lung cancer.New insights in beta-tubulin sequence analysis in non-small cell lung cancer.Doomed trials for promising adenoviruses: a rationale for success.Integral nutritional approach to the care of cancer patients: results from a Delphi panel.Localisation of COX-2 protein is different in breast ductal carcinoma and adjacent non-tumour ductal epithelium.Atrioventricular nodal blocking secondary to melanoma infiltrationPhospholipid hydroperoxide glutathione peroxidase (PHGPx) expression is downregulated in poorly differentiated breast invasive ductal carcinomaRetroperitoneal Castleman's disease with colon cancer. A rare associationEarly intervention with epoetin beta prevents severe anaemia in lung cancer patients receiving platinum-based chemotherapy: a subgroup analysis of the NeoPrevent studyMolecular biology of pancreatic cancerEPO-R expression patterns in resected gastric adenocarcinoma followed by adjuvant chemoradiation treatmentERCC1 and topoisomerase I expression in small cell lung cancer: prognostic and predictive implicationsThe combination of FOLFOX4 and bevacizumab may enable salvage surgery of unresectable liver metastases in colon cancer
P50
Q28611402-2FF5FB58-B979-4D8B-A643-ADF13FA813E6Q33519564-9CB4D2E8-9EAC-48B4-9710-E5D4E7218608Q34012467-7173B043-7126-42C6-A2B8-2EAE2009D0A6Q35692250-E2E8C64B-B814-4A88-B497-038119F5CABDQ35848954-256B53B0-C125-4A93-94B4-60E62E30142EQ36157581-C5A1CAC2-3FB3-41A4-977E-55666EA4416AQ36962487-C068E00C-A74B-4FD7-A4E8-F262411D5E7EQ36963807-4D4D19EC-E24D-4EE1-92C3-BA081505FED8Q37061584-39F256D3-6829-4D07-9B23-D860F06E1CCEQ37079439-EAB7D22D-5D3A-4A0D-A448-2ED6A3116290Q37877407-DBBFDC0D-A31C-4833-8C5B-2383A46FE972Q37890687-9CAA7D27-0B71-43F2-B9EB-17441DC564CEQ37956044-4A5C90F2-24F4-481C-9AE0-7E3D173C2F13Q38347818-D4E50AA6-EECC-492F-8AAB-47B0FE5E80CFQ39220127-3857C046-75EA-4234-86A7-0051A938C68DQ39348032-7634ACB1-4F62-4EC0-8740-0F9A09BD297EQ39356827-5B093D96-E2C5-4FA0-AE03-63927E769EBEQ39823915-A3152D26-293A-4959-8B36-AF364CA8F729Q39997738-F55963C6-DD26-4362-97C3-1A0016BEEE6AQ40174892-FDFDADE0-E64C-4E6D-8FDE-9B465F169483Q40319760-3785F250-7651-4481-B647-CB9516ED5936Q40578959-7AA1CFCE-4218-4A77-84CF-1B9A9ADCADA5Q43691979-B4C029F0-CEEB-40E3-84F6-7AE77AB1F338Q53827059-6962FA68-3DC4-4C57-9D0F-50C5F22B0496Q54646316-51ABD294-D566-48B4-9BE6-B652054D05D5Q73713200-1727C8DC-ED67-4515-AEAB-00507D5C158BQ80363032-0E1DD069-9C16-4154-B06B-575E113D760CQ81080480-E1B90568-BB23-4FA7-9374-9162FBC635F8Q81309415-76D1DE1A-FAA5-462A-8021-3203BE2F7C75Q81973822-44A31D2E-FEA8-4F69-A232-92E28D0FD49EQ82573739-8F22EE59-A6E7-4086-A0D3-182F07B84241Q83464784-4B03A915-74A2-4F44-8501-4054C3190579Q83622352-7CA99C3E-E3D7-421A-B5CC-289260C9F510
P50
description
researcher
@en
wetenschapper
@nl
name
C Belda-Iniesta
@en
C Belda-Iniesta
@nl
type
label
C Belda-Iniesta
@en
C Belda-Iniesta
@nl
prefLabel
C Belda-Iniesta
@en
C Belda-Iniesta
@nl
P106
P31
P496
0000-0003-3254-7492